An update on the role of leukotrienes in asthma.
An update on the role of leukotrienes in asthma.
复制标题
DOI：
10.1097/aci.0b013e32833489c3
复制
发表时间：
2010-02
影响因子：
2.8
通讯作者：
Henderson WR Jr
中科院分区：
文献类型：
--
作者：
Hallstrand TS;Henderson WR Jr
Leukotrienes (LT)s are lipid mediators involved in the pathogenesis of asthma. There is significant new information about the actions of LTs in asthma, and the evolving role of anti-LT therapies. We review recent findings on regulation of LT synthesis, biological function of LTs in disease models, and use of LT modifiers in clinical practice. Our understanding of the regulation of LT synthesis at a molecular level has greatly advanced. Recent evidence indicates that genetic variation in the leukotriene synthetic pathway affects the clinical response to LT modifiers. The participation of LTB4 in the allergic sensitization process in animal models suggests a larger role for LTB4 in asthma. Preclinical and in vitro models suggest that the cysteinyl LT (CysLT)s are important in airway remodeling. LTs are key mediators of exercise-induced bronchoconstriction (EIB) with recent studies demonstrating that LT modifiers reduce the severity of EIB during short-term and long-term use. LTs are clearly involved in airway inflammation and certain clinical features of asthma. Evolving evidence indicates that LTB4 has an important role in the development of asthma, and that CysLTs are key mediators of the airway remodeling process.
